Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Omnimmune Holdings (merged with Roughneck)

M&A STATUS
M&A LATEST DEAL TYPE
2 FINANCING ROUNDS
Description

Developer of cancer therapeutic medicines. The company provides diagnostic and prognostic technologies for cancer treatment.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Primary Office
  • 4550 Post Oak Place Drive
  • Suite 224
  • Houston, TX 77027
  • United States

Omnimmune Holdings (merged with Roughneck) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Omnimmune Holdings (merged with Roughneck)‘s full profile, request access.

Request full access to PitchBook

Omnimmune Holdings (merged with Roughneck) Executive Team (2)

Name Title Board
Seat
Contact
Info
Harris Lichtenstein Chief Executive Officer, President, Director & Founder

1 Former Executive

You’re viewing 1 of 2 executives. Get the full list »